Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAY1225 in T2DM Inadequately Controlled With Diet and Exercise
NCT07139535Phase 3Not yet recruiting
- Sponsor
- Raynovent Biotech
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of RAY1225 in type 2 diabetes mellitus (T2DM), sponsored by Raynovent Biotech. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
RAY1225
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07139535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139535.